英文摘要 |
Recently there has been a controversy surrounding the Covid-19 vaccine trials recruitment in Taiwan. Some argue that the government and celebrities should not promote trial recruitment because it is against the regulation for recruiting study subjects for drug clinical trials. The authors analyze this controversy and the related issues presented to the Institutional Review Board (IRB) when reviewing recruitment advertisement. We found that the scope of recruitment regulation and the practice of recruitment through research subject pools may have been misinterpreted. Furthermore, reviewers of drug administration and IRB should be mindful that recruitment advertisement is protected by the freedom of speech, and should avoid placing unnecessary restrictions on it. To clarify the ambiguity in recruitment regulation and to circumvent similar conflicts that may arise, we propose to amend the current recruitment regulation. |